Payment overview · 2025
General Payments
$214.73
11 reported records · 7 companies
Healthcare provider profile · identity verified
John Jason White, MD
Allopathic & Osteopathic Physicians|Internal Medicine · AUGUSTA, GA · NPI 1699878108
Verified facts
What the public records show
CMS Open Payments records show John Jason White, MD received $214.73 in general payments during 2025 across 11 reported records.
Novartis Pharmaceuticals Corporation accounted for 31.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $67.60 | 31.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.65 | 17.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $31.52 | 14.7% | 2 | 2025 |
| Vital Connect, Inc | Unresolved — no canonical attribution shown | $26.50 | 12.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.07 | 10.3% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.01 | 7.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.38 | 6.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $214.73 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $67.60 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.65 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $31.52 | 2 | 2025 |
Source payment records
|
|||||
| VITALPATCH RTM Normalized: vitalpatch rtm |
Device | Vital Connect, Inc | $26.50 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 437 | 114 |
| Atorvastatin Calcium | Atorvastatin Calcium | 406 | 117 |
| Amlodipine Besylate | Amlodipine Besylate | 339 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 318 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 197 | 60 |
| Gabapentin | Gabapentin | 171 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 156 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 53 |
| Synthroid | Levothyroxine Sodium | 147 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 146 | 40 |
| Lisinopril | Lisinopril | 133 | 38 |
| Potassium Chloride | Potassium Chloride | 132 | 41 |
| Allopurinol | Allopurinol | 130 | 31 |
| Losartan Potassium | Losartan Potassium | 130 | 32 |
| Furosemide | Furosemide | 124 | 43 |
| Omeprazole | Omeprazole | 123 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 118 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 111 | 31 |
| Simvastatin | Simvastatin | 111 | 25 |
| Eliquis | Apixaban | 110 | 25 |
| Lorazepam | Lorazepam | 110 | 21 |
| Trazodone Hcl | Trazodone Hcl | 108 | 28 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 102 | 32 |
| Metformin Hcl | Metformin Hcl | 99 | 27 |
| Jardiance | Empagliflozin | 93 | 20 |
| Ezetimibe | Ezetimibe | 92 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 84 | 21 |
| Tramadol Hcl | Tramadol Hcl | 84 | 16 |
| Sertraline Hcl | Sertraline Hcl | 82 | 21 |
| Methylprednisolone | Methylprednisolone | 77 | 58 |
| Spironolactone | Spironolactone | 77 | 22 |
| Irbesartan | Irbesartan | 74 | 16 |
| Clonazepam | Clonazepam | 70 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 67 | 29 |
| Mounjaro | Tirzepatide | 65 | suppressed |
| Alprazolam | Alprazolam | 64 | 23 |
| Carvedilol | Carvedilol | 64 | 14 |
| Azithromycin | Azithromycin | 63 | 58 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 13 |
| Metformin Hcl Er | Metformin Hcl | 62 | 17 |
| Meloxicam | Meloxicam | 61 | 18 |
| Ozempic | Semaglutide | 61 | 11 |
| Myrbetriq | Mirabegron | 60 | 11 |
| Celecoxib | Celecoxib | 58 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 57 | 14 |
| Diazepam | Diazepam | 53 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 53 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 53 | 11 |
| Mirtazapine | Mirtazapine | 52 | 16 |
| Ondansetron Odt | Ondansetron | 52 | 37 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 11 |
| Aripiprazole | Aripiprazole | 50 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 37 |
| Bupropion Xl | Bupropion Hcl | 48 | 12 |
| Donepezil Hcl | Donepezil Hcl | 48 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 15 |
| Estradiol | Estradiol | 46 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 11 |
| Nifedipine Er | Nifedipine | 44 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 15 |
| Alendronate Sodium | Alendronate Sodium | 42 | suppressed |
| Famotidine | Famotidine | 42 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 40 | 14 |
| Prednisone | Prednisone | 40 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Atenolol | Atenolol | 39 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 38 | suppressed |
| Cephalexin | Cephalexin | 37 | 29 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 36 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 36 | 36 |
| Repatha Sureclick | Evolocumab | 35 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 28 |
| Auryxia | Ferric Citrate | 31 | suppressed |
| Eszopiclone | Eszopiclone | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Olanzapine | Olanzapine | 29 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 26 |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Fluconazole | Fluconazole | 25 | 19 |
| Glimepiride | Glimepiride | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Livalo | Pitavastatin Calcium | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 11 |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 11 |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 13 |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Sirolimus | Sirolimus | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Ridaura | Auranofin | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $214.73 · 11 records | Novartis Pharmaceuticals Corporation | Cologuard Collection Kit, INSPIRE, LEQVIO, NEXLETOL, TRELEGY ELLIPTA, VITALPATCH RTM, XIFAXAN | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error